Difference between revisions of "Triptorelin (Trelstar LA)"
m |
|||
| Line 34: | Line 34: | ||
[[Category:FDA approved in 2000]] | [[Category:FDA approved in 2000]] | ||
| + | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 13:33, 22 August 2022
General information
Class/mechanism: GnRH (gonadotropin-releasing hormone)/LHRH (luteinizing hormone releasing hormone) agonist; inhibits gonadotropin secretion, decreasing circulating levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone), and suppressing synthesis of ovarian and testicular steroids.[1][2]
Route: IM
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 6/15/2000: Initial FDA approval in the palliative treatment of advanced prostate cancer. (Based on Heyns et al. 2003)
Also known as
- Code names: AY25650, CL118532
- Generic name: triptorelin pamoate
- Brand names: Decapeptyl, Detryptoreline, Diphereline, Gonapeptyl, Trelstar LA, Variopeptyl